Riskpilot← Back to searchSign inGet full accessBIOPTIMATE ApS
APSActiveCVR 36051183Blokken 23Research and experimental development on natural sciences and engineering · NACE 7210Est. 20143 employees
Revenue 2024
DKK -2,1M
-58% vs 2023
EBITDA margin
288.7%
-20% vs 2023
Equity ratio
-41.2%
Financial strength
Net profit 2024
DKK -6,4M
-27% vs 2023
| Revenue | DKK -2,1M | -58% |
| EBITDA | DKK -6M | -20% |
| Net profit | DKK -6,4M | -27% |
| Total assets | DKK 9,4M | +656% |
| Equity | DKK -3,9M | +56% |
| Employees | 3 | — |
Legal name
BIOPTIMATE ApS
CVR number
36051183
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
18. juli 2014
Share capital
DKK 51.000
Employees
3 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af et medlem af bestyrelsen, af et medlem af bestyrelsen i forening med en direktør, eller af den samlede bestyrelse.
Company purpose
Selskabets formål er at foretage forskning og anden eksperimentel udvikling inden for naturvidenskab og teknik.
Address
Blokken 23
Phone
+4531103440
Email
kem@bioptimate.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 14 | -13 | -20 | 13 | -294 | -63 | -317 | -517 | -4.998 | -2.076 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -3.917 |
| EBITDA | 14 | -13 | -20 | 13 | -294 | -63 | -317 | -517 | -4.998 | -5.993 |
| Depreciation & amort. | -0 | -0 | -2 | -3 | -3 | -2 | -5 | -2.623 | -0 | -109 |
| EBIT | 14 | -13 | -22 | 9 | -297 | -65 | -323 | -3.139 | -4.998 | -6.102 |
| Net financials | 0 | 63 | -2 | -0 | -0 | -0 | -2 | -1 | 0 | -265 |
| Profit before tax | 14 | 50 | -24 | 11 | -298 | -65 | -325 | -3.141 | -4.997 | -6.367 |
| Tax | 5 | 11 | 0 | -2 | -7 | -5 | -71 | 86 | -0 | -0 |
| Net profit | 9 | 39 | -24 | 13 | -290 | -60 | -253 | -3.226 | -4.997 | -6.367 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 105 | 120 | 97 | 106 | 112 | 398 | 389 | 567 | 1.238 | 9.354 |
| Equity | 60 | 99 | 75 | 88 | -202 | -262 | -515 | -3.741 | -8.739 | -3.856 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 45 | 21 | 22 | 18 | 315 | 660 | 903 | 4.308 | 9.977 | 13.210 |
| Total debt | 45 | 21 | 22 | 18 | 315 | 660 | 903 | 4.308 | 9.977 | 13.210 |
EBITDA margin
-599283600.0%
This company
15.8%
Market median
-3792934277% vs market
20152024
Equity ratio
-41.2%
This company
38.2%
Market median
-208% vs market
20152024
Return on equity
-636711800.0%
This company
18.4%
Market median
-3460390317% vs market
20152024
Net profit margin
-636711800.0%
This company
8.1%
Market median
-7860639606% vs market
20152024
Asset turnover
-0.22×
This company
1.12×
Market median
-120% vs market
20152024
Debt / equity
3.43×
This company
0.62×
Market median
-453% vs market
20152024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2014-07-18 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
KE Chief Executive Officer | Chief Executive Officer | 2014 | — | — |
SS Management | Management | 2014 | — | — |
JC Management | Management | 2025 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2024 | — | — | |
| Chairman | 2020 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Pure20 ApS | Company | 100.0% | 100.0% | 2024 |
SD Venture Holding ApS | Company | 66.7% | 66.7% | 2020 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Pure20 Holding ApS
BIOPTIMATE ApS Board members of BIOPTIMATE ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Keld Ejdrup Markedal | Chief Executive Officer | 0 companies |
| Steen Simonsen | Management | 0 companies |
| Jens Christian Sørensen | Management | 0 companies |
| Jacob Sjørslev Frandsen | Board of Directors | 0 companies |
| Nicolai Winding Andersen | Chairman | 0 companies |